Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Statins are known to lower levels of LDL cholesterol, protect against cardiovascular disease, and slightly increase the risk of type 2 diabetes. This analysis of genetic variants in 112,772 participants from 14 studies suggests that PCSK9 inhibitors may do the same.
Monoclonal antibodies and other therapies that inhibit proprotein convertase sub...
Alternative Titles
Full title
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1852672073
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1852672073
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1604304
